Vivos Therapeutics to Present at Small Cap Showcase Amid OSA Market Expansion
Event summary
- Vivos Therapeutics CEO Kirk Hunstman to present at Small Cap Showcase on June 9, 2026, in New York City.
- Company to hold one-on-one meetings with pre-qualified investors during the event.
- Vivos' FDA-cleared CARE devices target obstructive sleep apnea (OSA) in adults and children.
- OSA affects over 1 billion people globally, with 80% undiagnosed.
The big picture
Vivos Therapeutics is positioning itself as a key player in the underserved OSA market, where diagnostic gaps and treatment inefficiencies persist. The company's FDA-cleared CARE devices offer a non-invasive alternative to traditional therapies, aligning with broader industry shifts toward patient-centric, non-pharmaceutical solutions. The Small Cap Showcase presentation could catalyze investor interest as Vivos seeks to expand its commercial footprint.
What we're watching
- Market Penetration
- How Vivos will leverage investor interest to scale its OSA treatment solutions amid high undiagnosed rates.
- Regulatory Dynamics
- Whether FDA clearance for pediatric OSA will drive adoption in the children's healthcare segment.
- Competitive Positioning
- The pace at which Vivos can differentiate itself from legacy OSA treatments like CPAP.